Join the 'Macular Edema' group to help and get support from people like you. How it works
Macular Edema Blog
| Tweet |
FDA Approves Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion
Posted 23 Jun 2010 by Drugs.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 23, 2010 - Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO). The FDA approved this new indication after a six-month Priority Review. "This approval provides an important new medicine for people experiencing the unexpected vision loss associated with macular edema following RVO," said Hal Barron, M.D., executive vice president, Global Development and chief medical officer. "In the Lucentis RVO clinical trials significantly more people treated with monthly Lucentis showed sustained vision improvement during the six-month study with an effect seen as early as seven days." About the Studies The BRAVO study assessed the safety and efficacy profile of Lucentis in a ... Read more
Related support groups: Macular Degeneration, Lucentis, Macular Edema, Ranibizumab
Drug-Laser Combination Proves Effective For Diabetic Blindness
Posted 28 Apr 2010 by Drugs.com
Drug-Laser Combination Proves Effective For Diabetic blindness [Los Angeles Times] From Los Angeles Times (CA) (April 28, 2010) Apr. 28--For the first time in a quarter of a century, researchers have identified a new treatment for diabetic macular edema, a potentially blinding disorder that affects about 1 million Americans, researchers said Tuesday. The treatment uses a drug called ranibizumab, which when administered in combination with laser phototherapy is twice as effective at reversing vision loss as laser therapy alone. Laser therapy to prevent leakage of blood vessels in the retina has been the gold standard since it was introduced in 1985. The findings were reported online in the journal Ophthalmology. Nearly 50% of those who received both the drug and phototherapy had a visual improvement of at least two lines on an eye chart, compared with 28% of those receiving only ... Read more
Related support groups: Lucentis, Macular Edema, Diabetic Retinopathy, Ranibizumab
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
Lucentis, Ozurdex, Ocu-Dex, Decadron Ocumeter, AK-Dex, Maxidex, ranibizumab, Dexasol